Trial Outcomes & Findings for Quercetin in Coronary Artery By-pass Surgery (NCT NCT04907253)

Last Updated: 2026-04-15

Results Overview

Circulating blood levels of hs-CRP (mg/L) will be measured as well as a panel of circulating inflammatory markers in a subgroup of patients at day 5 post-surgery

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

100 participants

Primary outcome timeframe

Baseline, 1 day and 4 days post-surgery

Results posted on

2026-04-15

Participant Flow

coronary unit patients waiting for CABG surgery

Participant milestones

Participant milestones
Measure	Placebo receive placebo BID	Quercetin reveive quercetin 500mg twice a day
Overall Study STARTED	50	50
Overall Study COMPLETED	50	47
Overall Study NOT COMPLETED	0	3

Reasons for withdrawal

Reasons for withdrawal
Measure	Placebo receive placebo BID	Quercetin reveive quercetin 500mg twice a day
Overall Study Withdrawal by Subject	0	3

Baseline Characteristics

Quercetin in Coronary Artery By-pass Surgery

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Placebo n=50 Participants Placebo BID	Quercetin n=47 Participants Quercetin 500mg BID	Total n=97 Participants Total of all reporting groups
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=193 Participants	0 Participants n=193 Participants	0 Participants n=386 Participants
Age, Categorical <=18 years	0 Participants n=193 Participants	0 Participants n=193 Participants	0 Participants n=386 Participants
Age, Categorical Between 18 and 65 years	25 Participants n=193 Participants	17 Participants n=193 Participants	42 Participants n=386 Participants
Age, Categorical >=65 years	25 Participants n=193 Participants	30 Participants n=193 Participants	55 Participants n=386 Participants
Age, Continuous	67 years STANDARD_DEVIATION 2 • n=193 Participants	68 years STANDARD_DEVIATION 1 • n=193 Participants	67 years STANDARD_DEVIATION 1 • n=386 Participants
Sex: Female, Male Female	11 Participants n=193 Participants	8 Participants n=193 Participants	19 Participants n=386 Participants
Sex: Female, Male Male	39 Participants n=193 Participants	39 Participants n=193 Participants	78 Participants n=386 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	50 Participants n=193 Participants	47 Participants n=193 Participants	97 Participants n=386 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=193 Participants	0 Participants n=193 Participants	0 Participants n=386 Participants
Region of Enrollment Canada	50 participants n=193 Participants	47 participants n=193 Participants	97 participants n=386 Participants
Inflammatory status (hs-CRP values)	7.6 mg/L STANDARD_DEVIATION 2.5 • n=193 Participants	7.1 mg/L STANDARD_DEVIATION 1.8 • n=193 Participants	7.3 mg/L STANDARD_DEVIATION 1.5 • n=386 Participants

PRIMARY outcome

Timeframe: Baseline, 1 day and 4 days post-surgery

Population: Men and women treated with quercetin or placebo starting 2 days before surgery

Circulating blood levels of hs-CRP (mg/L) will be measured as well as a panel of circulating inflammatory markers in a subgroup of patients at day 5 post-surgery

Outcome measures

Outcome measures
Measure	Placebo n=50 Participants Placebo BID	Quercetin n=47 Participants Quercetin 500mg BID
Quercetin-associated Change in Surgery-associated Inflammation Baseline men	7 mg/L Standard Deviation 2	8 mg/L Standard Deviation 3
Quercetin-associated Change in Surgery-associated Inflammation t1 men	113 mg/L Standard Deviation 6	119 mg/L Standard Deviation 6
Quercetin-associated Change in Surgery-associated Inflammation Baseline Women	9 mg/L Standard Deviation 5	3 mg/L Standard Deviation 1
Quercetin-associated Change in Surgery-associated Inflammation t1 women	87 mg/L Standard Deviation 10	109 mg/L Standard Deviation 16
Quercetin-associated Change in Surgery-associated Inflammation t4 women	85 mg/L Standard Deviation 10	19 mg/L Standard Deviation 17
Quercetin-associated Change in Surgery-associated Inflammation t4 men	127 mg/L Standard Deviation 8	128 mg/L Standard Deviation 7

PRIMARY outcome

Timeframe: Baseline, 1 day and 4 days post-surgery

Population: Men and women treated with quercetin or placebo starting 2 days before surgery

Circulating blood levels of ANGPTL2 (ng/L) will be measured in addition to additional circulating markers of inflammation in a sub-group of patients at day 4 post-surgery

Outcome measures

Outcome measures
Measure	Placebo n=47 Participants Placebo BID	Quercetin n=50 Participants Quercetin 500mg BID
Quercetin-associated Change in Surgery-associated Marker of Senescence Baseline women	6.8 ng/L Standard Error 0.5	5.5 ng/L Standard Error 0.4
Quercetin-associated Change in Surgery-associated Marker of Senescence t1 women	6.7 ng/L Standard Error 0.4	7.4 ng/L Standard Error 1.0
Quercetin-associated Change in Surgery-associated Marker of Senescence t4 women	7.5 ng/L Standard Error 0.6	7.3 ng/L Standard Error 0.4
Quercetin-associated Change in Surgery-associated Marker of Senescence baseline men	5.8 ng/L Standard Error 0.3	6.2 ng/L Standard Error 0.2
Quercetin-associated Change in Surgery-associated Marker of Senescence t1 men	7.0 ng/L Standard Error 0.3	7.0 ng/L Standard Error 0.2
Quercetin-associated Change in Surgery-associated Marker of Senescence t4 men	7.2 ng/L Standard Error 0.3	7.5 ng/L Standard Error 0.3

SECONDARY outcome

Timeframe: During surgery

Population: Acetylcholine Concentration (nM) Required for EC50 in Endothelium-dependent Relaxation

A discarded segment of the mammary artery will be collected at the end of the cardiac surgery when available. One portion of the segment will be used to study the endothelium-dependent relaxation ex vivo. Segments will be mounted on a wire myograph. After an equilibration period, it will be pre-contracted with U46619 (0.1 µM): when the pre-contraction is stable, a cumulative dose-response curve to acetylcholine is built to induce an endothelium-dependent relaxation. Relaxation will be determined by the vascular sensitivity to acetylcholine (nM). IMPORTANT: at completion of the study, the analysis revealed that during the surgery, only 34 arterial segments from patients in the quercetin group and 44 segments from patients in the placebo group were made available by the surgeon. Therefore, only these 78 arterial segments were analyzed for this outcome measure of the ITT population (n=97).

Outcome measures

Outcome measures
Measure	Placebo n=34 artery Placebo BID	Quercetin n=44 artery Quercetin 500mg BID
Acetylcholine Concentration (nM) Required for EC50 in Endothelium-dependent Relaxation	101 nM Interval 7.0 to 228.0	151 nM Interval 48.0 to 409.0

OTHER_PRE_SPECIFIED outcome

Timeframe: Three month post-surgery

Population: No event (death, recurrent angina, graft failure) occured after surgery during the following 3 months

Any event that occured during the three months following surgery

Outcome measures

Outcome data not reported

Adverse Events

Placebo

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Quercetin

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr Eric Thorin

Montreal Heart Institute

Phone: 514-376-3330

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place